Graham Jackson

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · The Lancet · 2010 · 566 citations · Full text

Hematological Malignancy, Zoledronic Acid, Oncology +8

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell et al. · Journal of Clinical Oncology · 2015 · 557 citations · Full text

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Blood · 2018 · 478 citations · Full text

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Leukemia · 2018 · 440 citations · Full text

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Andy C. Rawstron, J. A. Child, Ruth M. de Tute et al. · Journal of Clinical Oncology · 2013 · 406 citations